| Literature DB >> 15753939 |
Alex Cardenas1, Jonas Fontenot, Kenneth M Forster, Craig W Stevens, George Starkschall.
Abstract
We describe a method for evaluating the quality of respiratory-gated radiation delivery using a commercially available device. During irradiation, gating traces for one field for each treatment were extracted from the system for each of 14 patients. The data were then transferred to a spreadsheet. Software was developed to evaluate the following parameters: duty cycle, amplitude of fiducial motion, fraction of amplitude of motion during gated delivery, and respiratory cycle time. Criteria were established for acceptability of gating traces. In our sample, over 85% of the traces indicated acceptability. An example of results for one patient extracted from analyzed gating traces is as follows: mean duty cycle, 57%, average amplitude of motion, 0.89 cm, average fraction of motion during gated delivery, 0.45; mean respiratory cycle time, 4.5 s. This technique can be used to evaluate delivery of respiratory-gated radiation therapy for quality assurance purposes and to assess various techniques for improving delivery of gated therapy. A hardcopy of the gating traces can be used to document gated treatment delivery for potential billing of the gated delivery process.Entities:
Mesh:
Year: 2004 PMID: 15753939 PMCID: PMC5723481 DOI: 10.1120/jacmp.v5i3.2002
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Figure 1The IR source and CCD detector that constitute the Varian RPM™ system
Summary of patients included in study
| Patient | Tumor location | Stage | Diagnosis |
|---|---|---|---|
| 1 | left bronchus/lung | I | adenocarcinoma |
| 2 | liver | III | adenocarcinoma |
| 3 | liver | unresectable | intrahepatic cholangiocarcinoma |
| 4 | left upper lobe | I | nonsmall cell |
| 5 | right middle lobe | IV | nonsmall cell |
| 6 | right upper lobe | IIIB | nonsmall cell |
| 7 | right upper lobe | III | nonsmall cell |
| 8 | right lower lobe | II | adenocarcinoma |
| 9 | right upper lobe | I | nonsmall cell |
| 10 | left lung | III | squamous cell carcinoma |
| 11 | liver | IV | adenocarcinoma |
| 12 | left upper lobe | I | nonsmall cell |
| 13 | right upper lobe | I | nonsmall cell |
| 14 | left upper lobe | II | nonsmall cell |
Figure 2Amplitude of vertical motion of reflective box during a patient treatment
Figure 3Amplitude of motion while radiation was being delivered under gating
Results of gating analysis for each patient
| Patient | Duty cycle | Respiratory amplitude | Fraction of motion during delivery | Respiratory cycle time |
|---|---|---|---|---|
| 1 |
|
|
|
|
| 2 |
|
|
|
|
| 3 |
|
|
|
|
| 4 |
|
|
|
|
| 5 |
|
|
|
|
| 6 |
|
|
|
|
| 7 |
|
|
|
|
| 8 |
|
|
|
|
| 9 |
|
|
|
|
| 10 |
|
|
|
|
| 11 |
|
|
|
|
| 12 |
|
|
|
|
| 13 |
|
|
|
|
| 14 |
|
|
|
|
Figure 4Sample recording form for gated treatment delivery. The form displays three gated treatments, although typically perhaps 30 treatments might be displayed.